Abstract
Patients with recurrent cervical cancer have a poor response to standard chemotherapy. Although cemiplimab, new anti-PD-1 drug, showed superiority over chemotherapy in improving overall survival, its cost-effectiveness is not necessarily clarified. This study aimed to evaluate the cost-effectiveness of cemiplimab for recurrent cervical cancer from the payer’s perspective in Japan.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
